Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.83
CBPO's Cash to Debt is ranked higher than
53% of the 1430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. CBPO: 0.83 )
CBPO' s 10-Year Cash to Debt Range
Min: 0.83   Max: 16.33
Current: 0.83

0.83
16.33
Equity to Asset 0.48
CBPO's Equity to Asset is ranked higher than
61% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CBPO: 0.48 )
CBPO' s 10-Year Equity to Asset Range
Min: 0.29   Max: 0.67
Current: 0.48

0.29
0.67
Interest Coverage 30.06
CBPO's Interest Coverage is ranked higher than
51% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBPO: 30.06 )
CBPO' s 10-Year Interest Coverage Range
Min: 6.9   Max: 93.8
Current: 30.06

6.9
93.8
F-Score: 5
Z-Score: 8.81
M-Score: -2.74
WACC vs ROIC
14.07%
43.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 45.70
CBPO's Operating margin (%) is ranked higher than
98% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -90.24 vs. CBPO: 45.70 )
CBPO' s 10-Year Operating margin (%) Range
Min: 21.04   Max: 51.58
Current: 45.7

21.04
51.58
Net-margin (%) 29.15
CBPO's Net-margin (%) is ranked higher than
96% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. CBPO: 29.15 )
CBPO' s 10-Year Net-margin (%) Range
Min: 1.86   Max: 29.15
Current: 29.15

1.86
29.15
ROE (%) 34.21
CBPO's ROE (%) is ranked higher than
98% of the 1309 Companies
in the Global Biotechnology industry.

( Industry Median: -30.42 vs. CBPO: 34.21 )
CBPO' s 10-Year ROE (%) Range
Min: 5.04   Max: 42.37
Current: 34.21

5.04
42.37
ROA (%) 16.51
CBPO's ROA (%) is ranked higher than
96% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: -25.96 vs. CBPO: 16.51 )
CBPO' s 10-Year ROA (%) Range
Min: 1.84   Max: 23.86
Current: 16.51

1.84
23.86
ROC (Joel Greenblatt) (%) 58.94
CBPO's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -335.68 vs. CBPO: 58.94 )
CBPO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 53.26   Max: 254.82
Current: 58.94

53.26
254.82
Revenue Growth (3Y)(%) 18.20
CBPO's Revenue Growth (3Y)(%) is ranked higher than
88% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. CBPO: 18.20 )
CBPO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 8.3   Max: 57.5
Current: 18.2

8.3
57.5
EBITDA Growth (3Y)(%) 36.60
CBPO's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. CBPO: 36.60 )
CBPO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 5.5   Max: 72.3
Current: 36.6

5.5
72.3
EPS Growth (3Y)(%) 59.50
CBPO's EPS Growth (3Y)(%) is ranked higher than
97% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. CBPO: 59.50 )
CBPO' s 10-Year EPS Growth (3Y)(%) Range
Min: 6.7   Max: 156.1
Current: 59.5

6.7
156.1
» CBPO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CBPO Guru Trades in Q1 2014

Jim Simons 130,375 sh (+10.11%)
Chuck Royce 2,900 sh (unchged)
» More
Q2 2014

CBPO Guru Trades in Q2 2014

Jim Simons 200,100 sh (+53.48%)
Steven Cohen 8,000 sh (unchged)
Chuck Royce 2,900 sh (unchged)
» More
Q3 2014

CBPO Guru Trades in Q3 2014

Jim Simons 222,600 sh (+11.24%)
Chuck Royce 2,900 sh (unchged)
Steven Cohen Sold Out
» More
Q4 2014

CBPO Guru Trades in Q4 2014

Pioneer Investments 5,525 sh (New)
Jim Simons 276,100 sh (+24.03%)
Chuck Royce 2,900 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CBPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 34.80
CBPO's P/E(ttm) is ranked higher than
93% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBPO: 34.80 )
CBPO' s 10-Year P/E(ttm) Range
Min: 2.92   Max: 124.23
Current: 34.8

2.92
124.23
Forward P/E 23.42
CBPO's Forward P/E is ranked higher than
90% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBPO: 23.42 )
N/A
PE(NRI) 35.50
CBPO's PE(NRI) is ranked higher than
94% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBPO: 35.50 )
CBPO' s 10-Year PE(NRI) Range
Min: 2.92   Max: 129.2
Current: 35.5

2.92
129.2
P/B 11.10
CBPO's P/B is ranked lower than
52% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 6.80 vs. CBPO: 11.10 )
CBPO' s 10-Year P/B Range
Min: 0.84   Max: 11.7
Current: 11.1

0.84
11.7
P/S 10.14
CBPO's P/S is ranked higher than
72% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 37.92 vs. CBPO: 10.14 )
CBPO' s 10-Year P/S Range
Min: 0.68   Max: 10.7
Current: 10.14

0.68
10.7
PFCF 34.20
CBPO's PFCF is ranked higher than
95% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBPO: 34.20 )
CBPO' s 10-Year PFCF Range
Min: 1.92   Max: 35.7
Current: 34.2

1.92
35.7
POCF 26.95
CBPO's POCF is ranked higher than
95% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBPO: 26.95 )
CBPO' s 10-Year POCF Range
Min: 1.62   Max: 26.95
Current: 26.95

1.62
26.95
EV-to-EBIT 22.38
CBPO's EV-to-EBIT is ranked higher than
96% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBPO: 22.38 )
CBPO' s 10-Year EV-to-EBIT Range
Min: 1.2   Max: 23.8
Current: 22.38

1.2
23.8
PEG 1.79
CBPO's PEG is ranked higher than
99% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBPO: 1.79 )
CBPO' s 10-Year PEG Range
Min: 0.43   Max: 2.02
Current: 1.79

0.43
2.02
Shiller P/E 74.80
CBPO's Shiller P/E is ranked higher than
93% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBPO: 74.80 )
CBPO' s 10-Year Shiller P/E Range
Min: 27.89   Max: 77.8
Current: 74.8

27.89
77.8
Current Ratio 2.32
CBPO's Current Ratio is ranked higher than
61% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. CBPO: 2.32 )
CBPO' s 10-Year Current Ratio Range
Min: 1.14   Max: 4.66
Current: 2.32

1.14
4.66
Quick Ratio 1.48
CBPO's Quick Ratio is ranked higher than
57% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. CBPO: 1.48 )
CBPO' s 10-Year Quick Ratio Range
Min: 0.54   Max: 3.07
Current: 1.48

0.54
3.07
Days Inventory 430.68
CBPO's Days Inventory is ranked higher than
77% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBPO: 430.68 )
CBPO' s 10-Year Days Inventory Range
Min: 280.18   Max: 490.33
Current: 430.68

280.18
490.33
Days Sales Outstanding 29.11
CBPO's Days Sales Outstanding is ranked higher than
92% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 128.03 vs. CBPO: 29.11 )
CBPO' s 10-Year Days Sales Outstanding Range
Min: 2.44   Max: 39.95
Current: 29.11

2.44
39.95

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 11.90
CBPO's Price/Tangible Book is ranked higher than
55% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 9.90 vs. CBPO: 11.90 )
CBPO' s 10-Year Price/Tangible Book Range
Min: 1.16   Max: 24.65
Current: 11.9

1.16
24.65
Price/DCF (Projected) 3.50
CBPO's Price/DCF (Projected) is ranked higher than
94% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBPO: 3.50 )
CBPO' s 10-Year Price/DCF (Projected) Range
Min: 1.08   Max: 2.46
Current: 3.5

1.08
2.46
Price/Median PS Value 4.90
CBPO's Price/Median PS Value is ranked higher than
62% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 3.04 vs. CBPO: 4.90 )
CBPO' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 3.46
Current: 4.9

0.45
3.46
Price/Peter Lynch Fair Value 2.00
CBPO's Price/Peter Lynch Fair Value is ranked higher than
98% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBPO: 2.00 )
CBPO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.85   Max: 1.38
Current: 2

0.85
1.38
Price/Graham Number 3.60
CBPO's Price/Graham Number is ranked higher than
93% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBPO: 3.60 )
CBPO' s 10-Year Price/Graham Number Range
Min: 0.38   Max: 4.03
Current: 3.6

0.38
4.03
Earnings Yield (Greenblatt) 4.60
CBPO's Earnings Yield (Greenblatt) is ranked higher than
95% of the 1388 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. CBPO: 4.60 )
CBPO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.2   Max: 84.3
Current: 4.6

4.2
84.3
Forward Rate of Return (Yacktman) 19.28
CBPO's Forward Rate of Return (Yacktman) is ranked higher than
83% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 15.79 vs. CBPO: 19.28 )
CBPO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 19.1   Max: 35.3
Current: 19.28

19.1
35.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0CB.Germany,
China Biologic Products, Inc. was originally incorporated on December 20, 1989 under the laws of the State of Texas as Shepherd Food Equipment, Inc. On November 20, 2000, Shepherd Food Equipment, Inc. changed its corporate name to Shepherd Food Equipment, Inc. Acquisition Corp., which is the survivor of a merger with GRC Holdings, Inc. on May 28, 2003. On January 10, 2007, the Company was converted into a Delaware corporation and changed its name to China Biologic Products, Inc. It is a biopharmaceutical company which is engaged in the research, development, manufacturing and sales of human plasma-based pharmaceutical products in China. The Company has two majority subsidiaries, Shandong Taibang, a company based in Tai'an, Shandong Province and Guizhou Taibang, a company based in Guiyang, Guizhou Province. The Company's products are human albumin and immunoglobulin products. Albumin has been used for almost 50 years to treat critically ill patients by replacing lost fluid and maintaining adequate blood volume and pressure. Immunoglobulin is used for certain disease prevention and treatment by enhancing specific immunity. These products use human plasma as the principal raw material. Human albumin and human immunoglobulin for intravenous injection, or IVIG products, are the top-selling products. The Company sells its products primarily to hospitals and inoculation centers in the PRC directly or through approved distributors.
» More Articles for CBPO

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: ULTA, MIND, DG, PSA, CBPO, CNK Dec 20 2011 
Weekly CEO Sells Highlight: CTSH, CBPO, TCB, SRCL Sep 12 2010 
China Biologic Products Amends Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biol Dec 19 2008 

More From Other Websites
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Apr 16 2015
China Biologic Receives Approval to Purchase Raw Materials Apr 16 2015
China Biologic Receives Approval to Purchase Raw Materials Apr 16 2015
Warburg Pincus Reaps $1 Billion Betting on China’s Blood Market Apr 08 2015
CHINA BIOLOGIC PRODUCTS, INC. Financials Mar 12 2015
China Biologic Products posts 4Q profit Mar 04 2015
China Biologic Products posts 4Q profit Mar 04 2015
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 Mar 04 2015
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 04 2015
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 Mar 04 2015
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 10-K, Annual Report Mar 04 2015
Q4 2014 China Biologic Products Inc Earnings Release - After Market Close Mar 04 2015
China Biologic Products CBPO) Falls: Stock Goes Down 6% - Tale of the Tape Feb 25 2015
China Biologic Products (CBPO) Catches Eye: Stock Up 6% - Tale of the Tape Feb 18 2015
China Biologic Products to Report Fourth Quarter and Fiscal Year 2014 Financial Results Feb 17 2015
China Biologic Products to Report Fourth Quarter and Fiscal Year 2014 Financial Results Feb 17 2015
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 09 2015
China Biologic Adopts Stockholder Rights Plan Jan 08 2015
China Biologic Adopts Stockholder Rights Plan Jan 08 2015
China Biologic Receives GMP Certification for New Coagulation Factor Facility Dec 23 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK